ASCO 2023: New Research From Memorial Sloan Kettering Cancer Center Identifies Significant Treatment Advancement for Brain Tumors
June 05, 2023
June 05, 2023
NEW YORK, June 5 (TNSjou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on June 4, 2023:
Breakthrough data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in The New England Journal of Medicine (NEJM) today found that vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progressi . . .
Breakthrough data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in The New England Journal of Medicine (NEJM) today found that vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progressi . . .